Skip to main content

Updates On a Treatment Option For Certain Patients With Unresectable or Metastatic HER2+ Breast Cancer

March 26, 2021

Brought to you by Daiichi Sankyo, Inc.

Please join Daiichi Sankyo, Inc. and AstraZeneca on Thursday April 29th at 9AM EST for an expert-led discussion to explore updates on the treatment of certain patients with unresectable or metastatic HER2+ breast cancer (mBC). This program is intended to provide attendees with a deeper understanding of a treatment option which addresses a key unmet need for previously treated HER2+ mBC. This session will not only cover the unmet needs of HER2+ mBC patients who have received prior therapies, but provide an overview of the efficacy, key safety considerations, and management of this treatment option. This program is intended for US healthcare professionals. To register for this live program, visit 

Blog category